Clinical value of prophylactic liver protecting drugs in coronavirus disease 2019 (COVID-19)

Objective To explore and analyze the incidence of liver injury in patients with coronavirus disease 2019(COVID-19) and the clinical value of diammonium glycyrrhizinate preventive liver protection. Methods A total of 66 patients with COVID-19 diagnosed in Huai'an from January 23 to March 9, 2020 were randomly divided into observation group (n=34) and control group (n=32). The observation group was given antiviral treatment, symptomatic treatment and diammonium glycyrrhizinate enteric coated capsule prophylactic liver protection treatment, while the control group was only given antiviral treatment and symptomatic treatment. The changes of liver function indexes alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and γ-glutamyl transpeptidase (GGT) were observed before treatment, and at 1 week and 2 weeks after treatment. Results There was no significant difference in ALT and AST levels between the two groups before treatment (P>0.05); At 1 week and 2 weeks after treatment, the levels of ALT and AST were significantly lower in the observation group than in the control group (P＜0.05). There was no significant difference in ALP and GGT between the two groups before treatment and at 1 week and 2 weeks after treatment (P>0.05). Conclusions Diammonium glycyrrhizinate has protective effect on liver function of patients with covid-19.